Engineered TCR therapy targeting lipid antigens in AML 2306228
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has a poor prognosis with a 5-year overall survival of ∼30%. While CAR-T has revolutionized the treatment of other hematological malignancies, it has been difficult to replicate this same success in AML. Healthy myeloid cells often share e...